A Phase 3 trial of cancer drug Nexavar in patients with advanced breast cancer failed to delay progression of the disease, according to the drug’s makers, Bayer and Onyx Pharmaceuticals, Inc., an Amgen subsidiary.
The study, called Reslience, evaluated Nexavar in combination with capecitabine, an oral chemotherapeutic agent, in patients with HER2-negative breast cancer.
The drug is approved to treat certain types of liver, kidney and thyroid cancer and works by targeting signalling pathways that tumor cells use to survive. Researchers hoped that Nexavar would have the same tumor-stalling effect on breast growths.
“We are disappointed that the trial did not show an improvement in progression-free survival in patients with advanced breast cancer,” Dr. Joerg Moeller, Member of the Bayer HealthCare Executive Committee and Head of Global Development, said in a statement. “While the primary endpoint of this trial was not met, the trial results do not affect the currently approved indications for Nexavar. We would like to thank the patients and the study investigators for their contributions and participation in this study.”
Data from the study will be presented at an upcoming scientific conference.
- LeBron James Could Take Pickleball—Yes, Pickleball—to the Next Level
- It's Going to Be a Lot More Expensive to Heat Your Home This Winter. Here's What To Expect
- The U.S. Might Be the Surprising Determining Factor in the Future of Armenia
- Rapper Saucy Santana Is Opening a Door For His Community
- Here are the Biggest Moments from the TIME100 Leadership Forum and Impact Awards in Singapore
- Column: Russia Wants to Lock Ukraine Back in the Soviet Cellar
- As the Kanjuruhan Tragedy Shows, Indonesia Has Not Resolved Its Long-Standing Problem of Soccer Violence
- Here's Everything New on Netflix in October 2022
- A New Documentary Series Illuminates the History and Evolution of Queer Horror